New information from sentinel lymph node studies in breast cancer

BY DEBU TRIPATHY
PUBLISHED: JUNE 07, 2010
Over the last decade, the use of sentinel node biopsy has reduced the number of patients who need a full axillary lymph node dissection for treatment and staging of breast cancer.

This represents a very important advance because a sentinel node biopsy is much less likely to lead to long term lymphedema--chronic swelling of the arm that can have a large impact on day-to-day activities and quality of life. However, when one or more sentinel nodes, which are identified by using a blue colored dye and radioactive tracer, are found to contain tumor cells, a full axillary dissection is recommended.

Sentinel node biopsies are done in patients who do not have any nodes felt on physical examination, but about one third of patients who are found to have tumor in the sentinel nodes are currently treated with follow-up complete surgery.

To determine whether additional surgery and its attendant risks are really needed, the American College of Surgeons conducted a trial to see if patients with up to three positive sentinel nodes could be spared a full dissection. This randomized trial compared no further surgery to full dissection in such patients, and the results showed no difference in the number of patients that had a recurrence in the breast or under the arm--about 3 to 4 percent overall, with six years of follow-up.

In the commentary provided on this abstract it was stated that these results are "practice changing" and if adopted, would make a big difference in the side effect profile of breast surgery in the estimated 50,000 of patients who undergo axillary dissection in the United States.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
x
//For side ad protocol